OCGN Ocugen Inc

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200
EN
06/10/2020

Underlying

OCGNOcugen Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocugen Inc

 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confi...

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathies MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been s...

April 1, 2026 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Tr...

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approved therapies at 12 and 24 months, respectivelyNo serious adverse events and no adverse events of special interest related to OCU410 reported to date MALVERN, Pa., March 2...

March 24, 2026 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss P...

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage d...

March 23, 2026 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025...

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second qu...

March 4, 2026 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a...

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RPPositive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrates sustained clinically mea...

March 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch